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Introduction {#sec005}
============

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis, microvascular disease, and presence of autoantibodies. In China, two fatal manifestations, interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), are the most common SSc complications among connective tissue diseases \[[@pone.0166629.ref001],[@pone.0166629.ref002]\]. Thus, classification of SSc during the early disease stages is critical so that treatment can begin sooner. The first widely accepted classification criteria for SSc were published in 1980, and the high specificity of 1980 criteria helped minimize false-positive diagnoses \[[@pone.0166629.ref003]\]. Nonetheless, improved classification criteria that could diagnose SSc even earlier were urgently needed. In 2001 LeRoy and Medsger proposed modifications to the criteria used to diagnose early SSc \[[@pone.0166629.ref004]\]. Recently, a joint committee of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) formulated a new set of SSc classification criteria, which has proven to have increased sensitivity over the 1980 criteria while still preserving the specificity determined from studies conducted in other countries \[[@pone.0166629.ref005],[@pone.0166629.ref006]\]. The objective of this study was to validate the sensitivity and specificity of the new classification criteria in Chinese SSc patients.

Patients and Methods {#sec006}
====================

Patients {#sec007}
--------

Patients who were clinically diagnosed with SSc between September 2013 and May 2015 were prospectively recruited from the EUSTAR database of the Peking Union Medical College Hospital (PUMCH). Diagnosis of SSc was based on the evaluation of three experienced rheumatologists from PUMCH. SSc patients were not required to meet any formal classification criteria. Patients diagnosed with other connective tissue diseases were recruited as disease controls according to the respective classification criteria.

Pulmonary arterial hypertension (PAH) was defined as a mean pulmonary arterial pressure of \> 25 mmHg, together with a pulmonary capillary wedge pressure of \< 15 mmHg determined by right heart catheterization(RHC). Pulmonary fibrosis was defined as ground glass opacification or fibrosis on high-resolution computed tomography (HRCT).

Methods {#sec008}
-------

This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital and all subjects provided informed written consent. Demographic features, clinical characteristics (including Raynaud's phenomenon, puffy fingers, telangiectasias, and digital pitting), and laboratory findings (anti-centromere, anti-Scl-70, and anti-RNA polymerase III antibodies, echocardiography and HRCT, and nailfold videocapillaroscopy (NVC) test) were collected for all patients. Patients were classified into limited and diffuse cutaneous subsets based on the definition of Leroy *et al*. \[[@pone.0166629.ref004]\]. Disease duration was defined as the time from the first non-RP SSc manifestation to entry. The 1980 ACR and 2013 ACR/EULAR criteria were applied to evaluate the patients diagnosed with SSc clinically and disease controls; patients who fulfilled each criterion were classified as definite SSc patients. Sensitivity and specificity were evaluated for each set of classification criteria. Sensitivity for various SSc subgroups was also evaluated.

Statistical analysis {#sec009}
--------------------

The Statistical Package for the Social Sciences (SPSS) version 17.0 (SPSS, Chicago, IL) was used for data processing and analysis. Quantitative results were presented as mean ± standard deviation (normal distribution), or median, interquartile range (non- normal distribution). The x2 test was used to analyze enumeration data. P \< 0.05 was considered to be statistically significant.

Results {#sec010}
=======

A total of 143 SSc patients and 87 patients with other connective diseases were recruited for this study ([Table 1](#pone.0166629.t001){ref-type="table"}). All patients were of Han nationality. Of the 143 SSc patients, 41 (28.7%) and 102 (71.3%) cases were diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc), respectively. Disease duration was 63.15 ± 59.32 months. 137 of 143 patients with SSc had RP, and it was the initial symptom in 113 patients. The duration from RP and first symptom to entry were 86.61±78.22 months and 87.18±77.22 months, respectively. The clinical features of SSc patients and disease controls are listed in [Table 2](#pone.0166629.t002){ref-type="table"}. On the other hand, pulmonary artery systolic pressure \> 40 mmHg at rest based on an echocardiogram test was present in 33 patients in 143 SSc patients. 22 in 33 patients had done the RHC and were confirmed to have PAH. Though the other 11 patients didn't do the RHC, no matter whether PAH was present in these patients, the validation results for 1980 and 2013 criteria were same. Rodnan scores were 5.0 ± 5.6 in SSc patients. The other clinical features were as following: joint involvement 41.3% (59/143), myositis 10.5% (15/143), gastrointestinal involvement 59.4% (85/143), gastroesophageal reflux 49.7% (71/143), heart conduction block 2.8% (4/143), and scleroderma crisis 0%.

10.1371/journal.pone.0166629.t001

###### Disease spectrum of other connective tissue diseases used as controls.

![](pone.0166629.t001){#pone.0166629.t001g}

                                  Cases (%)   RP Cases
  ------------------------------- ----------- ------------
  SLE                             45 (51.7)   32
  Polymyositis /Dermatomyositis   14 (16.1)   2
  MCTD                            9 (10.3)    9
  UCTD                            6 (6.9)     5
  Systemic vasculitis             5 (5.7)     1
  Primary Sjögren's syndrome      5 (5.7%)    2
  Fasciitis                       2(2.3%)     0
  Localized scleroderma           1(1.1%)     0
  Total                           87          51 (58.6%)

SLE, systemic lupus erythematosus; MCTD, Mixed connective tissue disease; UCTD, undifferentiated connective tissue disease; RP,Raynaud's phenomenon.

10.1371/journal.pone.0166629.t002

###### The demagraphic and clinical features of SSc patients and disease controls.

![](pone.0166629.t002){#pone.0166629.t002g}

                                 SSc patients (n = 143)   Disease controls (n = 87)   P value
  ------------------------------ ------------------------ --------------------------- ---------
  Age (years)                    46.92 ± 11.74            38.72 ± 11.91               \<0.001
  Gender (F/M)                   133/10                   73/14                       0.029
  RP                             137 (95.8%)              52 (59.8%)                  \<0.001
  Puffy fingers                  68 (47.6%)               18 (20.7%)                  \<0.001
  Sclerodactyly                  111 (77.6%)              2 (2.3%)                    \<0.001
  Digital ulcers                 37 (25.9%)               4 (4.6%)                    \<0.001
  Pitting scars                  21 (14.7%)               2 (2.3%)                    0.002
  Telangiectasias                52 (36.4%)               2 (2.3%)                    \<0.001
  PAH                            22/132 (16.7%)           13 (14.9%)                  0.135
  ILD                            104 (72.7%)              25 (28.7%)                  \<0.001
  ACA                            23 (16.1%)               6 (6.9%)                    0.042
  Anti-Scl70 antibody            57 (39.3%)               3 (3.4%)                    \<0.001
  Anti-polymerase III antibody   0(0%)                    0(0%)                       1.000

RP, Raynaud's phenomenon; PAH, pulmonary arterial hypertension; ILD, interstitial lung disease; ACA, anticentromere antibody.

Of the 143 SSc and 87 other disease patients, 104 and 2 patients, respectively, satisfied the 1980 criteria. On the other hand, 135 of the 143 SSc patients and 6 of 87 patients in the other connective diseases group satisfied the 2013 criteria. The sensitivity of the 2013 classification criteria for SSc (94.4%) exceeded the 1980 classification criteria (72.7%) (P\<0.001). However, there was no significant difference between the specificity of the two classification criteria (93.1% and 97.7% for 2013 and 1980, respectively; P = 0.278).

Further, we did a sensitivity analysis excluding patients with MCTD since these patients frequently had prominent SSc features and often evolved into SSc, The results were similar. Of the 143 SSc and 78 other disease patients, 104 and 2 patients, respectively, satisfied the 1980 criteria. On the other hand, 135 of the 143 SSc patients and 5 of 78 patients in the other connective diseases group satisfied the 2013 criteria. The sensitivity of the 2013 classification criteria for SSc 94.4% exceeded the 1980 classification criteria 72.7% (P\<0.001).

The sensitivities of the 1980 ACR and 2013 ACR/EULAR in various subgroups of SSc patients were further evaluated. There were no significant differences between 1980 and 2013 criteria in male (90% vs. 90%), dsSSc (97.6% vs. 100%), presence of digital ulcers (86.5% vs. 100%), presence of pitting scars (85.7% vs. 100%), absence of abnormal NVC patterns (86.4% vs. 86.4%), absence of RP (50% vs. 66.7%), anti-Scl70 antibody positivity (96.5% vs. 100%). On the other hand, there were significant increased sensitivity in 2013 than 1980 criteria in female (71.4% vs. 94.7%), lcSSc (62.7% vs. 92.2%), absence of digital ulcers (67.9% vs. 92.5%) or pitting scars(70.5% vs. 93.4%), presence of abnormal NVC patterns (70.2% vs. 95.9%) or RP (73.7% vs. 95.6%), anti-Scl70 antibody negativity(57% vs. 90.7%). Moreover, there were also significant increased sensitivity in 2013 than 1980 criteria in disease duration \< 3 or ≥ 3 years, presence or absence of Sclerodactyly, telangiectasia, PAH, ILD, ACA and anti-RNP antibody.

Discussion {#sec011}
==========

Skin thickening is a characteristic manifestation of SSc, and many physicians recognize this disease by this feature. However, the diagnosis of SSc patients with mild skin thickening always was delayed. That was a deficiency for the 1980 ACR SSc classification criteria. Consistent with previous studies that examined disease characteristics in patients of other nationalities, our study also showed that the 2013 ACR/EULAR SSc classification criteria had improved sensitivity without affecting specificity in Chinese Han populations \[[@pone.0166629.ref005],[@pone.0166629.ref006],[@pone.0166629.ref007]--[@pone.0166629.ref010]\] ([Table 3](#pone.0166629.t003){ref-type="table"}). Also, the 2013 ACR/EULAR criteria had significantly increased sensitivity relative to the 1980 criteria in most SSC patient subgroups, with the exception of patients with more extensive skin thickening, e.g., diffuse cutaneous SSc. These patients had a high rate of diagnosis even using 1980 criteria due to extensive skin involvement. The 2013 ACR/EULAR criteria had higher sensitivity in patients with mild skin thickening. Interestingly, in our study we found that the 2013 criteria did not produce increased sensitivity in either male patients or patients who were positive for anti-Scl-70 antibody, which may be due to the greater frequency of dcSSc patients in these two subgroups (60% and 53%, respectively).

10.1371/journal.pone.0166629.t003

###### Sensitivity and specificity of 1980 ACR and 2013 ACR/EULAR criteria in different countries.

![](pone.0166629.t003){#pone.0166629.t003g}

                                                                  Patient numbers                                1980 ACR   2013 ACR/EULAR                  
  --------------------------------------------------------------- ---------------------------------------------- ---------- ---------------- ------ ------- -------
  ACR/EULAR (13 centers in North America, 10 centers in Europe)                                                                                             
   Derivation sample \[[@pone.0166629.ref005]\]                   100                                            100        81               77     95      93
   Validation sample \[[@pone.0166629.ref005]\]                   268                                            137        75               72     91      92
  Turkey (3 centers) \[[@pone.0166629.ref006]\]                   131                                            103        85.3             100    94.4    98.1
  Canada (15 centers) \[[@pone.0166629.ref007]\]                  724                                                       88.3                    98.3    
  Norway (single center) \[[@pone.0166629.ref008]\]               391/425[\*](#t003fn001){ref-type="table-fn"}   178        75                      96      90
  Switzerland (single center) \[[@pone.0166629.ref009]\]          304                                                       53.5                    79.6    
  Spain(single center)\[[@pone.0166629.ref010]\]                  106                                            221        76.4             96.5   98.1%   94.6%
  Our study (single center)                                       143                                            87         72.7             97.7   94.4    93.1

\*Because prescleroderma and sine SSc, by definition, would not be tested by the 1980 ACR criteria, only 391 patients was classifiable by 1980 criteria

On the other hand, NVC is widely used to differentiate secondary RP from primary RP \[[@pone.0166629.ref011]\]. The 2013 criteria includes the NVC test, and our study showed the sensitivity of the 2013 criteria was significantly increased relative to the 1980 criteria in patients with an abnormal NVC pattern, but there was no difference between the old and new criteria for patients with a normal NVC pattern. As we know, abnormal NVC pattern could indicate and accompany with the presence of other microvascular diseases, for example Raynaud's phenomenon, PAH, and telangiectasia., and these manifestations of microvascular diseases were all included in the 2013 criteria, but not in the 1980 criteria. This maybe was the reason for increased sensitivity in patients with an abnormal NVC pattern. Similarly, one study from a capillaroscopy clinic showed that one of individual variables in 2013 criteria with the best sensitivity was capillaroscopic abnormalities(81.1%)\[[@pone.0166629.ref010]\]. SSc patients with prominent microvascular diseases maybe could be classified earlier with the 2013 criteria.

To date, only four studies have evaluated the specificity of the old and/or new criteria. As with previous studies, our study showed that the specificity of the 2013 and 1980 criteria was high and the two criteria sets exhibited no significant differences. However, the 1980 criteria had higher specificity than that determined by the ACR/EULAR group, which is similar to results obtained in studies performed in Turkey and Spain. These differences could be due to the choice of controls. The characteristics of the controls in the Turkey study and our study were similar, and almost all control patients had connective tissue diseases with ANA positivity. However, the ACR/EULAR study included more cases with non-CTD scleroderma-like diseases, which had skin thickening similar to that seen in SSc. The inclusion of these patients may thus reduce the specificity of the 1980 criteria in the ACR/EULAR study.

This is the first study to evaluate the performance of the new 2013 criteria in a Han Chinese population. In Chinese SSc patients, the new 2013 criteria had higher sensitivity and similar specificity compared with the 1980 criteria, especially in patients with mild skin thickening or prominent microvascular diseases. It could clarify the SSc patients at earlier stage.

Supporting Information {#sec012}
======================

###### Primiary data of patients with systemic sclerosis.

This is the data about the patients with SSc.

(XLS)

###### 

Click here for additional data file.

###### Primiary data of patients with disease control.

This is the data about the patients with disease control.

(XLS)

###### 

Click here for additional data file.
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